Home › Kanser sa Pantog › Michigan › Detroit
Pag-aaral pangklinika para sa Kanser sa Pantog sa Detroit, MI
Isang pag-aaral para sa Kanser sa Pantog ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Detroit. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
The Vanguard Study: Testing a New Way to Screen for Cancer
Nagre-recruitMalugod na tinatanggap ang malusog na boluntaryo
- Henry Ford Hospital, Detroit
- Henry Ford Medical Center - Detroit Northwest, Detroit
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
- Henry Ford Hospital, Detroit
- Henry Ford Health Saint John Hospital, Detroit
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Nagre-recruitPhase 2
- Henry Ford Hospital, Detroit
- Henry Ford Health Saint John Hospital, Detroit
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Nagre-recruitPhase 3
- Karmanos Cancer Institute, Detroit
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Nagre-recruitPhase 1
- Barbara Ann Karmanos Cancer Institute, Detroit
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
Nagre-recruitPhase 3
- Henry Ford Hospital, Detroit
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Nagre-recruitPhase 1/2
- Karmanos Cancer Institute, Detroit
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Nagre-recruitPhase 1/2
- Henry Ford Health System, Detroit
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Nagre-recruitPhase 2/3
- Karmanos Cancer Institute, Detroit
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Nagre-recruitPhase 2
- Karmanos Cancer Institute, Detroit
- Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion), Detroit
A Beta-only IL-2 ImmunoTherapY Study
Nagre-recruitPhase 1/2
- Karmanos Cancer Institute, Detroit
Pag-aaral para sa Kanser sa Pantog sa ibang lungsod
- New York City, NY35 pag-aaral
- Houston, TX31 pag-aaral
- Nashville, TN31 pag-aaral
- Dallas, TX27 pag-aaral
- Washington, DC26 pag-aaral
- Boston, MA26 pag-aaral
- Baltimore, MD24 pag-aaral
- Los Angeles, CA24 pag-aaral
- St. Louis, MO22 pag-aaral
- Seattle, WA21 pag-aaral
- Philadelphia, PA21 pag-aaral
- Chicago, IL21 pag-aaral
Iba pang pag-aaral sa Detroit
- Non-Small Cell Lung Cancer44 pag-aaral
- Kanser sa Suso33 pag-aaral
- Kanser (lahat ng uri)29 pag-aaral
- Colorectal Cancer26 pag-aaral
- Kanser sa Ovary26 pag-aaral
- Metastatic Cancer24 pag-aaral
- Kanser sa Prostate22 pag-aaral
- Kanser ng Endometrium21 pag-aaral
- Kanser sa Baga20 pag-aaral
- Multiple Myeloma19 pag-aaral
- Kanser sa Tiyan16 pag-aaral
- Squamous Cell Carcinoma ng Ulo at Leeg15 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.